Our data indicate that FHL2 silencing reduces osteosarcoma cell tumorigenesis in vitro and in vivo, indicating that FHL2 is a potential target for therapeutical intervention in this type of cancer. This evidence concerns the gene FHL2 and osteosarcoma.